The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of EGFR mutation on definitive concurrent chemoradiation therapy for inoperable stage III lung adenocarcinoma.
Kosuke Tanaka
No relevant relationships to disclose
Tomoyo Oguri
No relevant relationships to disclose
Tatsuya Yoshida
No relevant relationships to disclose
Jangchul Park
No relevant relationships to disclose
Junichi Shimizu
No relevant relationships to disclose
Yoshitsugu Horio
No relevant relationships to disclose
Takeshi Kodaira
No relevant relationships to disclose
Toyoaki Hida
No relevant relationships to disclose